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Aggregation of alpha-synuclein (α-syn) is considered to be the major pathological
hallmark and driving force of Multiple System Atrophy (MSA) and Parkinson’s disease
(PD). Immune dysfunctions have been associated with both MSA and PD and recently
we reported that the levels of natural occurring autoantibodies (NAbs) with high-
affinity/avidity toward α-synuclein are reduced in MSA and PD patients. Here, we
aimed to evaluate the plasma immunoglobulin (Ig) composition binding α-syn and
other amyloidogenic neuropathological proteins, and to correlate them with disease
severity and duration in MSA and PD patients. All participants were recruited from
a single neurological unit and the plasma samples were stored for later research at
the Bispebjerg Movement Disorder Biobank. All patients were diagnosed according
to current consensus criteria. Using multiple variable linear regression analyses, we
observed higher levels of anti-α-syn IgG1 and IgG3 NAbs in MSA vs. PD, higher
levels of anti-α-syn IgG2 NAbs in PD compared to controls, whereas anti-α-syn IgG4
NAbs were reduced in PD compared to MSA and controls. Anti-α-syn IgM levels
were decreased in both MSA and PD. Further our data supported that MSA patients’
immune system was affected with reduced IgG1 and IgM global levels compared to PD
and controls, with further reduced global IgG2 levels compared to PD. These results
suggest distinct autoimmune patterns in MSA and PD. These findings suggest a specific
autoimmune physiological mechanism involving responses toward α-syn, differing in
neurodegenerative disease with overlapping α-syn pathology.
Keywords: autoimmunity, antigens, autoantibodies, neurology, plasma, alpha-synuclein, multiple system atrophy,
parkinson’s disease
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INTRODUCTION
Multiple system atrophy (MSA) and Parkinson’s disease (PD)
are neurodegenerative movement disorders which share many
clinical and pathomorphological features (1, 2). The pathological
hallmark for these two diseases is the aggregation of the protein
α-synuclein (α-syn), which precipitates as glial cytoplasmic
inclusions in oligodendroglia in MSA and neuronal Lewy body
inclusions in PD (1). Furthermore, α-syn is also present in large
amounts in the blood of both patients and healthy individuals
and as inclusions in the enteric nervous system in PD (3, 4).
MSA is considered a sporadic disease of uncertain etiology,
whereas at least 90% of PD cases are idiopathic and ∼10%
represent rare Mendelian hereditary forms (1). Discriminating
between MSA and idiopathic PD can be difficult, especially
at early stages, but usually MSA presents a more pernicious
course. Advanced molecular imaging can, to some degree, aid
to distinguish PD from MSA and other atypical parkinsonism
syndromes (5), but definite diagnoses is only possible through
post-mortem examination (6). Hence, there is a need for more
convenient and sensitive biomarkers for the disorder, which has
great importance for prognostic measures and development of
therapeutic strategies.
Naturally occurring autoantibodies (NAbs) are components
of the innate immune system present throughout life. NAbs
recognize and bind self-antigens without prior immunization
(7). They are distinct from adaptive antibodies, which are
highly specific to exogenous pathogens to which the host has
experienced previous exposure. NAbs are predominantly of
IgM and IgG classes. Their main functions are maintenance of
physiological and immune homeostasis by, e.g., removing aging
cells, tumor cells, cellular debris, and altered self-molecules, to
inactivate cytokines, and to mask autoantigens (8). In recent
years, it has been suggested that IgMs constitute the first
line of defense against neoepitopes as reviewed by (9). It is
further believed that IgM NAbs are spontaneously produced
by memory B-1 cells and upon activation through the B cell
receptor, memory B cell proliferate and a majority Ig class-
switches e.g., IgG subclasses (10, 11). Quantitative and functional
differences in specific autoantigenic NAbs and/or changes of
NAb profiles over time within individuals have been associated
with various pathophysiological conditions (12, 13), including
neurodegenerative diseases (14). Indeed, a vast number of
studies have investigated α-syn specific NAbs in PD, often
with contradictory results. The majority of studies have found
unchanged anti-α-syn NAb levels (15–19) and increased levels
in early PD (15, 20–24). One study reported reduced anti-α-syn
NAb levels in PD (25). The only study reporting plasma levels
of anti-α-syn NAbs in atypical parkinsonism disorders reported
no differences in patients in a combined group including MSA,
Lewy body Dementia, another synucleinopathy, and Progressive
Supranuclear Palsy, a tauopathy, compared to controls and PD
(17). Furthermore, Orr et al. (26) showed that IgG deposits
co-localized with α-syn pathology in PD brains, suggesting
an induced pathological α-syn response. The inconsistency of
previous studies probably results from limitations in reporting
total levels of immunoglobulin (Ig)G autoantibodies, without
differentiating into α-syn reactive IgG subclasses and IgM. To
this date, no studies have evaluated levels of IgG subclasses and
IgM NAbs against any amyloidogenic proteins in a pure MSA
patient group and in PD patients.
Recently, we reported that the repertoire of high-
affinity/avidity IgG autoantibodies against α-syn was significantly
reduced in PD and almost absent in MSA (27). This implies
impaired capacity for immune clearance and/or blocking of toxic
α-synuclein species, which may reflect the distinct pathology
and symptom progression patterns in the two disorders. Based
on these results we hypothesized that the distributions of IgG
subclasses, i.e., IgG1-IgG4, total IgG and IgM, specific toward
α-syn, may show different α-syn autoimmune responses in MSA
and PD vs. controls. Moreover, we hypothesized that the humoral
aberrancy is confined to α-syn and to further examine whether
alterations are a general amyloidogenic tendency, we investigated
autoantibody subclass levels toward serine-129-phosphorylated
α-syn, and the closely related β- and γ-syn, together with
plasma levels of the dementia-associated amyloidogenic proteins
amyloid-β (Aβ) and tau. The levels of NAbs were additionally
correlated with disease severity and disease duration.
METHODS
Subjects and Samples
Plasma samples from patients with probable MSA (n = 34), PD
(n = 43), as well as control subjects (n = 59) were obtained
from the Bispebjerg Movement Disorder Biobank, Department
of Neurology, Bispebjerg-Frederiksberg Hospital, University
Hospital of Copenhagen, Copenhagen, Denmark. These were all
outpatients on ambulatory visit from August 2007 to September
2015 that had a blood sample taken for inclusion in the Bispebjerg
Movement Disorder Biobank. Patients were followed by a
Movement Disorder specialist. Patients at recruitment time were
given either a “possible” or a “probable” diagnosis of MSA and
PD according to consensus criteria (28, 29). Only individuals that
progressed from possible diagnosis at recruitment to probable
MSA diagnosis at the follow-up visit (after 2015) were included
in this study. Healthy control subjects were selected from the
same biobank based on the absence of any immunological
diseases or history of any neurological disorders including head
trauma. Individuals receiving immunomodulatory treatment
were not chosen for the study. All individuals in this study were
Caucasian, with a few exceptions. The preanalytical handling
was carried out according to previous recommendations for
biobanking except the centrifugation temperature was set at
5◦C (30). Briefly, venous whole blood was drawn to 7.5mL
EDTA tubes (Monovette, Sarstedt, Germany, cat# 01.1605.001)
and centrifuged at 2,000 × g for 10min at 5◦C within 30min
of collection. The plasma fraction was aliquoted in 400 µl
polypropylene cryotubes and stored at −80◦C within 90min.
The storage time between samples did not differ between MSA
patients [mean = 5.7 years; standard deviation (SD) = 2.3], PD
patients [mean = 5.2; SD = 0.7], and controls [mean = 5.5;
SD = 0.2]. Further, the measured outcomes did not correlate
with the storage time (Pearson’s r; p > 0.05). Demographic data
are summarized in Table 1. Age upon collection of the samples
was significantly lower in controls subjects compared to MSA
and PD patients (p < 0.001), and sex ratio differed significantly
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between PD and controls (p = 0.011). Further, as expected,
disease duration was significantly longer in PD (p = 0.03) and
MSA patients had more advanced disease severity (p < 0.001),
evaluated by Hoehn & Yahr (H & Y) staging (31). Hence, to avoid
confounding, all statistical analyses were adjusted for age and sex.
Measurement of Antigen-Specific
Autoantibodies
Initially, we investigated levels of antibodies toward the
pathological protein, α-syn. Moreover, to evaluate for the
specificity of the binding to α-syn, which is considered to be
an amyloidogenic protein, we included several other proteins
with similar properties. Hence, we measured the relative levels
of autoantibodies against full-length α-syn (rPeptide, USA, cat#
S-1001), beta(β)-syn (rPeptide, USA, cat# S-1003), gamma(γ)-
syn (rPeptide, USA, cat# S-1007), tau (2N4R) (rPeptide, USA,
cat# T-1001), and amyloid-β (1-42) (rPeptide, USA, cat# A-1002)
using indirect ELISA setups developed in-house. Autoantibody
levels toward Phosphorylated α-syn was measured as described
earlier (27). In details: (1) 96-well polystyrene plates (Nunc©
Maxisorp, cat# 144531) were coated with 50 µl portions of
recombinant protein monomers at a concentration of 5µg/ml
(for tau: 1µg/ml) in ice-cold 0.1M carbonate buffer at pH 9.4
for minimum 12 h at 4◦C. (2) The plates were then emptied
and blocked with 3% bovine serum albumin (BSA) fraction V
(Sigma-Aldrich, cat# 10735094001) containing 0.1% TergitolTM
solution (Sigma-Aldrich, cat# NP40S) in phosphate-buffered
saline (PBS) at pH 7.4 for 2 h at room temperature (RT). Wells
were washed in five consecutive washing steps with 300 µl/well
of PBS+0.05% Tween-20 (Sigma-Aldrich, cat# P1379) using a
WellWash instrument (Thermo Scientific, USA). (3) Diluted
plasma samples (1:100) in PBS containing 0.1% BSA were added
to the plates and incubated for 1 h at RT. For IgG4 assays, plasma
samples were diluted 1:50. (4) After a subsequent washing step,
the plates were incubated at RT for 2 h with 50 µl of biotinylated
secondary antibodies at the following concentrations: goat anti-
human total IgG 1:30,000 (Sigma-Aldrich, cat# SAB3701279,
RRID:AB_2783655), goat anti-human IgM (1:5,000; Sigma-
Aldrich, cat# B1265, RRID:AB_258514), mouse anti-human
IgG1 (1:1,000; Thermo Fisher Scientific, Cat# MH1515,
RRID:AB_2539710), mouse anti-human IgG2 (1:5,000: Sigma-
Aldrich, cat# B3398, RRID:AB_258546), mouse anti-human
IgG3 (1:500; Sigma-Aldrich, cat# B3523, RRID:AB_258549),
and mouse anti-human IgG4 (1:200; Sigma-Aldrich, cat#
B3648, RRID:AB_258555). After washing, 50 µl portions of
streptavidin-peroxidase (1:10,000; Sigma-Aldrich, cat# 5512)
were added to each well and incubated for 30min at RT. (5)
The plates were washed for the last time before the enzymatic
reaction was developed by adding 50 µl of tetramethylbenzidine
(TMB) Liquid Peroxidase Substrate (Sigma-Aldrich, cat# T8665)
and incubated in dark for 30min at RT. (6) The enzymatic
reaction was terminated by addition of 0.5N Sulfuric Acid
(Merck, cat# 109073), and (7) the optical density (OD) was
measured on a MultiscanTM FC Microplate reader (Fisher
ScientificTM) at 450/620 nm. Before final assays, extensive
optimization of each ELISA setup was done. Titer analyses
of each antibody was performed, which included analyses of
the positive controls on each plate to ensure homogeneity
between plates, yielding %CVs ranging from 5.0 to 7.6%.
Moreover, titer analyses were performed on coating and pooled
plasma samples for each separate experimental setup. We also
undertook Z’-factor analyses with Z’-factor values ranging
from 0.77 to 0.88. Moreover, All sample ODs were normalized
to a positive calibration control in a 2-fold serial dilution
with a primary antibody against coated proteins/antigens
and detected with a secondary biotinylated antibody specific
for the primary antibody, i.e., rabbit (1:1,000; Vector, cat#
TABLE 1 | Demographic and clinical data.
Controls
(n = 59)
MSA-C patients
(n = 11)
MSA-P patients
(n = 20)
MSA-C+P patients
(n = 3)
MSA patients
total (n = 34)
PD patients
(n = 43)
p-values
Male/female# 10/49 3/8 9/11 0/3 12/22 30/13 0.011*
Age, yearsΨ 41.2 (13.5)
[20-85]
65 (7.1) [52-77] 65.4 (10.1) [46-79] 60.7 (10.7) [49-70] 64.8 (9.1)
[46-79]§
62.8 (6.8)
[46-78]§
<0.001*
Age of onset$ – 57.6 (6.9) [42-67] 60 (10.4) [43-78] 55 (16.4) [37-69] 58.9 (9.8)
[37-78]
54.8 (9.1)
[37-74]
0.063
Disease duration,
years$
– 7.3 (6.5) [1-25] 5.2 (5.7) [0–22] 5.7 (5.6) [1-12] 5.9 (4.5) [0–25] 7.9 (5.3) [1-22]¤ 0.031*
Hoehn & Yahr staging 6= – 3.5 (1.0) [2-5] 3.1 (0.5) [2-4] 3.7 (0.6) [3-4] 3.3 (0.7) [2-5] 2.0 (0.26)
[1.5–3]¤
<0.001*
Results are presented as mean ± standard deviation [range]. MSA, Multiple System Atrophy; MSA-P, MSA with predominantly parkinsonian signs; MSA-C, MSA with predominantly
cerebellar signs; MSA-C+P, MSA with both parkinsonian and cerebellar signs. PD, Parkinson’s disease. All statistical analyses between MSA and PD were performed on total
MSA patients.
#Chi-squared test.
ΨOne-way ANOVA with combined MSA group.
$Student’s t test.
6=Mann-Whitney U-test.
*Significant p-value below 0.05.
§Significantly different from controls.
¤Significantly different from combined MSA.
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BA-1000, RRID:AB_2313606) or mouse (1:1,000; Vector, cat#
BA-9200, RRID:AB_2336171). The antibodies for the positive
controls were mouse anti-human α-synuclein (Abcam, cat#
ab27766, RRID:AB_727020), mouse anti-human β-synuclein
(Abcam, cat# ab167607, RRID:AB_2783654), mouse anti-
human γ-synuclein (Abcam, cat# ab89462, RRID:AB_2042990),
rabbit anti-human phospho-α-synuclein Ser129 (Santa Cruz,
cat# Sc-135638, RRID:AB_2302265), rabbit anti-Tau (Dako,
cat# A0024, RRID:AB_10013724), and mouse anti-human
amyloid-beta (Abcam, cat# ab2539, RRID:AB_303141).
Measurement of Global Antibody Plasma
Levels
To assess whether the global humoral immune system
encompassed the antigen-specific IgG subclass and IgM
responses, we measured the global concentrations of IgG
subclass and IgM antibodies in plasma samples. We have
used the commercially available Ready-SET-Go! R© ELISA kits
(Thermo Scientific Affymetrix eBioscience) following the
manufacturer’s instructions. In brief, plasma samples were
diluted in the assay buffers supplied with the kits according
to manufacturer-recommended: IgG1 ELISA kit: 1:2,000 (cat#
88-50560, RRID:AB_2574896); IgG2 ELISA kit: 1:500,000
(cat# 88-50570, RRID:AB_2574897); IgG3 ELISA kit: 1:40,000
(cat# 88-50580, RRID:AB_2574898); IgG4 ELISA kit: 1:1,000
(cat# 88-50590, RRID:AB_2574899); IgG-total ELISA kit:
1:500,000 (cat# 88-50550, RRID:AB_2574891), and IgM 1:20,000
(cat# 88-50620, RRID:AB_2574912).
Determination of α-Syn Concentration
To evaluate the potential effect of anti-α-syn NAbs on peripheral
α-syn levels, wemeasured total concentrations of α-syn in plasma
samples using the commercially available U-PLEX R© Human α-
syn Kit (MSD R© MULTI-ARRAY Assay System, cat# K151WKK)
following themanufacturer’s instructions. Prior the assessment of
the individual samples, we optimized the assay for greatest yield
using titer analyses in 1:50 diluted plasma. Plasma samples were
diluted 1:50 in Diluent 49 provided by the manufacturer. The
plates were read using an MSD Sector Imager S600.
Statistical Analyses
The data analyses were performed using R v. 3.5.2 (32), GraphPad
Prism v. 7.02 (GraphPad Software Inc., USA) and SPSS v. 24.0
(IBM, USA). Demographic differences were tested using one-
way ANOVA, unpaired Student’s t-test, Mann-Whitney U-
test, and the chi-squared test. Normality was assessed using
the D’Agostino Omnibus test and Shapiro Wilk test; if a
normality test failed, the data were log10-transformed. For group
comparisons, we used multiple linear regression modeling in R
including the covariates age and sex with contrast for group using
Anova from the car package (33). For multiple comparisons, the
glht and mcp functions from the multcomp package (34) were
applied to include covariates in post hoc testing using Tukey’s
range test. Correlation analyses were assessed using Spearman’s
Rank-Order correlation. Differences were considered significant
at p < 0.05. To compensate for potential Type I error for
multiple comparison of multiple linear regression modeling’s,
Bonferroni correction was performed with a significance cut-off
at p< 0.0013.
RESULTS
NAbs Against Pathological Antigens
Our model described significant differences in levels of α-syn
reactive antibodies for all IgG subclasses and IgMs [IgG1: F(4,109)
= 10.3, p = 3.9E-07; IgG2: F(4,114) = 8.4, p = 5.5E-06; IgG3:
F(4,120) = 6.0, p = 1.4E-04; IgG4: F(4,124) = 9.7, p = 7.6E-07]
and IgM [F(4,126) = 11.5, p = 5.4E-08; Figure 1], whereas the
total levels of anti-α-syn IgG NAbs were similar in all groups,
with neither age nor sex being significantly confounding factors.
The relative levels of anti-α-syn IgG1 were higher in MSA
compared to PD (p < 0.001; Figure 1B). Similarly, the anti-α-
syn IgG3 levels were higher in MSA compared to PD (p = 0.008;
Figure 1D). Anti-α-syn IgG2 levels described by disease group
(p = 3.0E-04) were higher in PD compared to controls (p <
0.001; Figure 1C), as were the described anti-α-syn IgG4 levels
by group (p= 3.5E-07), whereas anti-α-syn IgG4was lower in PD
compared to MSA and controls (controls: p = 0.005 and MSA: p
< 0.001; Figure 1E). Further, anti-α-syn IgM levels were lower in
both MSA and PD as compared to controls (MSA: p= 0.002 and
PD: p= 0.001) described by group (p= 6.0E-04; Figure 1F).
Further, our model identified increased anti-Tau IgG1 levels
in PD compared to MSA [F(4,125) = 5.0, p = 9.0E-04], also only
described by group (p = 1.0E-03) with decreased levels in MSA
compared to PD (p = 0.022; Figure S1). For detailed statistics
of each parameter and adjusted post hoc Tukey analyses see
Table S1.
Global Plasma Antibody Concentrations
The global antibody concentrations (total IgG, IgG1-4, and IgM)
are shown in Table 2 and presented in Figure 2. Interestingly, we
observed significantly lower global IgG1 levels [F(4,129) = 9.9, p=
5.2E-07] described by group (3.6E-04) in MSA compared to PD
and controls (both p< 0.001; Figure 2B). The levels of IgG2 were
also significantly lower [F(4,132) = 3.8, p = 6.0E-03] described
by group (p = 3.0E-03) in MSA compared to PD patients (p =
0.003), but not compared to controls (p= 0.084; Figure 2C).
Similar to IgG1 findings, there were significantly lower global
IgM levels [F(4,95) = 6.6, p = 1.0E-04] described only by group
(p = 3.0E-04) in MSA compared to PD (p = 0.001) and controls
(p= 0.003; Figure 2F). Besides being described by group, the IgM
levels were to a minor extent further described by sex [F(1) =
6.80, p = 0.011], indicating sex as a confounding factor in IgM
plasma levels. For detailed statistics see Table S2. Further, our
model showed IgG3 levels to be significantly different [F(4,130)
= 2.66, p = 0.035], however, this difference was not described
by group, age, or sex. No significant differences were observed
between the groups for IgG4 or total IgG levels.
Total Plasma α-Synuclein
Total levels of plasma α-syn were significantly described by
our model [F(2,125) = 7.46, p = 2.0E-05] described by group
[F(2) = 5.58, p = 5.0E-03] and were significantly lower in MSA
[479± 175 ng/mL; (223–885 ng/mL)] compared only to controls
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FIGURE 1 | Plasma α-synuclein naturally occurring autoantibody levels. Distribution of relative anti-α-synuclein naturally occurring autoantibody plasma levels in
patients with Multiple System Atrophy (MSA, n = 34) divided into subtypes (MSA-P: gray squares, n = 20; MSA-C: black triangles, n = 11; MSA-C+P, n = 3: white
rhombi), patients with Parkinson’s disease (PD, n = 34), and controls (n = 59). ELISA relative ODs of anti-α-synuclein (A) total IgG, (B) IgG1, (C) IgG2, (D) IgG3, (E)
IgG4, and (F) IgM autoantibodies. Dot plots show relative ODs with mean values (horizontal bars) ± SEM. Differences were tested using one-way ANOVA and Tukey’s
post hoc test adjusted for age and sex.
[638 ± 251 ng/mL; (155–1285 ng/mL)] (p = 0.014; Figure S2).
Total plasma α-syn levels were not significantly different in PD
[532 ± 170 ng/mL; (236–984 ng/mL); controls: p = 0.243; MSA:
p= 0.280].
Correlation to Clinical Outcomes
The aberrant levels of those individual NAbs or global antibodies
with significant described outcomes were correlated with disease
duration and H&Y staging. The anti-α-syn IgMNAbs correlated
significantly with disease duration in the PD group [Spearman’s
correlation (rho) = −0.389, p = 0.014; see Table S3]. Further, α-
syn levels in plasma correlated negatively with disease duration
in MSA (rho=−0.389, p= 0.028) and were positively associated
with the H & Y staging in PD (rho = 0.338, p = 0.04; see
Table S3).
DISCUSSION
To our knowledge, this is the first study exploring the global
concentrations of plasma IgM, total IgG, and IgG1-4 subclasses
along with subclass autoantibodies toward conventional
neuropathological amyloidogenic proteins i.e., α-syn, pSer129-
α-syn, β-syn, γ-syn, Aβ and tau protein, in MSA and PD
patients compared to a control group. Our data suggest that
the peripheral immune system is deregulated in MSA and PD,
constrained mainly toward α-syn, that in aggregated form is the
major pathological hallmark protein in MSA and PD.
We previously hypothesized that the relatively mild, but
significant, decrease in high-affinity/avidity anti-α-syn NAbs in
plasma of PD patients may parallel the relative slow progression
of PD pathology compared to MSA, whereas the rapidly
progressing clinical course of MSA could be related to the near
absence of high-affinity/avidity anti-α-synNAbs in that condition
(27). Consequently, in this study, we have made a detailed
investigation of the nature of the autoimmune decline in relation
to IgM and IgG1-4 levels.
The main finding of this study is the significantly reduced
anti-α-syn IgM levels in both MSA and PD patients compared
to healthy controls. Remarkably, the anti-α-syn IgM levels
were negatively correlated with disease duration in PD. Natural
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TABLE 2 | Global plasma immunoglobulin levels.
Group Amount (mg/dL) Range
Total IgG Controls 2,978 ± 1,888 249.9–7,002
(mg/dL) MSA 2,312 ± 1,511 191.6–6,585
PD 2,776 ± 1,872 86.03–7,109
IgG1 Controls 1,037 ± 518 207.1–2,417
(mg/dL) MSA 496 ± 291§, 6= 145–1,375
PD 916 ± 478# 143.7–2,232
IgG2 Controls 843 ± 422 169–2,328
(mg/dL) MSA 645 ± 288 6= 136.5–1,515
PD 1,022 ± 483# 212–2,609
IgG3 Controls 235 ± 134 43–574
(mg/dL) MSA 149 ± 75 43–344
PD 177 ± 108 46–516
IgG4 Controls 31.7 ± 20.4 2.5–95.4
(mg/dL) MSA 26.0 ± 15.1 2.8–58.5
PD 37.6 ± 26.6 4.2–112.7
IgM Controls 415 ± 316 53–1,204
(mg/dL) MSA 131 ± 66§ 54–278
PD 337 ± 272§ 63–933
Results are presented as mean± standard deviation. MSA, Multiple System Atrophy; PD,
Parkinson’s disease.
§Significantly different from controls.
#Significantly different from MSA.
6=Significantly different from PD.
For exact adjusted Tukey’s post-hoc p-values, see Figure 1. For complete model
statistics, see Table S2.
IgMs are evolutionarily-conserved proteins of the innate and
adaptive immune system that react with a variety of epitopes
expressed on both self- and non-self-antigens, which have
previously been associated with autoimmune and inflammatory
diseases (35). Natural IgMs are often the products of long-
lived, self-renewing B-1 cell clones that arise during immune
development without an absolute requirement for exogenous
antigenic stimulation (36). IgMs lead to opsonization of antigens,
are a potent activator of the classical complement pathway, and
mediates endocytosis through Fcµ receptors on phagocytotic
cells (37). Reduction of these peripheral IgM NAbs would
be matched by lower levels of antigen-antibody complexes,
thus reducing uptake of complexes by macrophages and other
phagocytotic cells.
Different antibody isotypes carry out different functions,
i.e., IgG but not IgM antibodies can penetrate tissue, where
they activate complement and bind Fc receptors on resident
macrophages and NK cells to induce antibody-dependent
cellular response (38). Total levels of anti-α-syn IgG were
the subject of several previous investigations, which yielded
discordant results, as reviewed by Scott et al. (39). While
there was no difference in total anti-α-syn IgG NAb levels
between MSA, PD and control groups, we found several
significant group differences in IgG subclass levels. Notably,
we found significantly higher levels of anti-α-syn IgG1 and
IgG3 in MSA compared to PD groups, increased levels of
anti-α-syn IgG2 in PD compared to controls and decreased
anti-α-syn IgG4 levels in PD compared to MSA and control
groups. IgG1 and IgG3 are predominately activating antibodies
of the classical complement pathway mediated by C1q (40).
In neurodegenerative diseases such as AD and PD, it is
known that accumulating pathological proteins elicit local pro-
inflammatory activation and chronic responses of microglial
activation, mediating clearance of the antigens through the
complement system (40). One post mortem study showed
complement activation to be associated with Lewy bodies
in PD (41). An increase in pro-inflammatory activating
autoantibodies could partly explain the microgliosis in MSA and
PD patients (42–45).
Immunocomplexes are the direct, natural, and real-time
products of an immune response and we can speculate at
this point that a substantial number of anti-α-syn antibodies
will be engaged by antigens and therefore not measurable
in ELISA with α-syn coated plates, unless the samples
were first mildly denatured to free up the antibodies. One
possible explanation for the lower antibody levels is that
the polyclonal NAbs are relatively selective for oligomers
and aggregates but have lower affinity/avidity for monomeric
antigen. Indeed, the α-syn immobilized on ELISA plates display
heterogenous epitopes, i.e., both monomeric epitopes and the
oligomeric/aggregated epitopes that are probably more attractive
for polyclonal NAbs.
To evaluate the distinctiveness of the α-syn autoantibody
patterns in MSA and PD, we have in this study also investigated
levels of antibodies to certain proteins involved in other
neurodegenerative diseases. We found that only the anti-
tau IgG1 levels were increased in PD compared to MSA.
A previous study has likewise shown alterations in anti-tau
NAbs against for PD patients with dementia (46). Present
results suggest that anti-tau and anti-Aβ NAbs do not play a
major role in MSA, but could contribute to PD pathogenesis,
especially in advanced or aggressive forms of the disease.
These results suggest that the immune system is responding
mainly toward the pathological hallmarks and not overall to
amyloidogenic proteins.
β-syn shows weak aggregation properties, whereas γ-syn
shows stronger aggregation properties, resembling those of α-
syn (47). However, neither β-syn nor γ-syn have any established
pathological relation in PD and MSA. Even though β-syn and
γ-syn present potentially overlapping epitopes with α-syn due
to their high amino acid sequence homology, 78% and 60%,
respectively (48), we did not identify any aberrant findings
for anti-β-syn or anti-γ-syn NAbs that survived correction for
multiple comparison.
Global IgM and IgG levels have not hitherto been evaluated
in MSA or PD. Notably, we found that the levels of global
plasma IgM and IgG1 were significantly lower in MSA compared
to PD and healthy control groups, and that global IgG2 levels
were still lower in MSA compared to PD patients. These global
antibody results may reflect systemic immunological differences
in MSA and PD compared with healthy individuals and
could furthermore indicate an especially decreased homeostatic
capability or selective immunodeficiency in MSA, perhaps
reflecting its more aggressive course.
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FIGURE 2 | Global plasma antibody levels. Distribution of global plasma amounts (mg/dL) of antibodies in patients with Multiple System Atrophy (MSA, n = 34)
divided into subtypes (MSA-P: gray squares, n = 20; MSA-C: black triangles, n = 11; MSA-C+P, n = 3: white rhombi), patients with Parkinson’s disease (PD, n = 34),
and controls (n = 59). Absolute plasma concentrations to ELISA of (A) total IgG, (B) IgG1, (C) IgG2, (D) IgG3, (E) IgG4, and (F) IgM antibodies. Dot plots show plasma
Ig concentrations with mean values (horizontal bars) ± SEM. Differences were tested using one-way ANOVA and Tukey’s post hoc test adjusted for age and sex.
At this point we can only speculate that the IgM producing
B-1 cell population may already be reduced or impaired in pre–
morbid MSA/PD individuals, resulting in an overload with toxic
α-syn species in the nervous system putting a greater burden
on the clearance mechanisms. In this scenario, after the initial
recognition of toxic α-syn species, the autoantibody response
changes to an IgG-dominated response characterized by lower-
affinity/avidity antibodies, as supported by present results. This
antigen-selective immunodeficiency in anti-α-syn NAbs can be
linked to the distinct clinical phenotypes of PD and MSA, with
MSA being much more rapidly progressing and having the more
severe α-syn accumulation (49, 50).
Plasma levels of α-syn have been extensively evaluated in
PD [reviewed in (39)], whereas only three studies have hitherto
measured α-syn levels in plasma from MSA patients (51–53).
We found that MSA patients had significantly lower plasma
α-syn compared to controls, thus in agreement with our previous
results (27) using similar methodology. However, this finding
stands in contrast to previous studies based on traditional
sandwich ELISAs, which suggested higher (51, 52) or unaltered
(53) plasma α-syn levels in MSA patients compared to controls.
We suppose that these discrepancies may be related either to
methodological difference or cohort composition. Nonetheless,
we observed that α-syn levels were negatively associated with
disease duration in MSA, an association that was absent in PD.
We suggest that the reason for the association in MSA could be
due to a wider or faster neurodegeneration, probable due to α-
syn aggregation. However, we identified a positive association
between α-syn levels and disease severity defined by H & Y
staging in PD patients in accordance with Lin et al. (54). This
suggests that peripheral levels of α-syn may play a role in the
pathogenesis of PD.
The study has some limitations. MSA is considered a rare
disorder, therefore, we had only access to a limited number
of MSA patients. Further, the patients were recruited out of
single neurological unit, hence our results should be validated
in a larger cohort, preferably in a longitudinal study. The two
disease groups were similar regarding demographics, however,
the control group included limitations regarding age and sex.
These two factors may have an impact on the humoral Ig
immune system, and even though we incorporated age and sex
as confounding variables in our statistical models, this need to be
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considered when interpreting the results. Nonetheless, our study
points to overlapping pathogenic mechanisms, as we identified
important trends in the humoral immune system of MSA and
PD patients.
In summary, we have found evidence for aberrant peripheral
IgM and IgG subclass responses in MSA and PD patients,
supporting involvement of an autoimmune component in
these disorders. The disease-specific α-syn antibody reactive
patterns suggest distinct processes of peripheral immune
pathogenesis in MSA and PD, which are potentially useful
for discriminative diagnosis. Our results indicate a reduced
capacity for immune clearance and/or blocking of toxic
α-syn transmission and propagation in these conditions,
and further support the rationale for immunotherapy
with high-affinity/avidity α-syn antibodies for treatment of
MSA and PD.
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